Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seagen Inc.    SGEN

SEAGEN INC.

(SGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seagen : to Host Conference Call and Webcast Discussion of Third Quarter 2020 Financial Results on October 29, 2020

10/14/2020 | 12:25pm EST

BOTHELL - Seagen Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2020 financial results on Thursday, October 29, 2020 after the close of U.S. financial markets.

Following the announcement, Company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: Thursday, October 29, 2020, 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time, Telephone 844-763-8274 (domestic) or +1 412-717-9224 (international); conference ID 10148256 Webcast with slides available at www.seagen.com in the Investors section. A webcast replay will be archived on the Company's website.

About Seagen

Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union.

Contact:

Peggy Pinkston

Tel: (425) 527-4160

Email: ppinkston@seagen.com

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about SEAGEN INC.
11/16Didi Chuxing, BYD roll out customized vans for ride-hailing service
RE
11/09SEAGEN : Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtua..
BU
11/05SEAGEN : Announces Multiple ADCETRIS« (Brentuximab Vedotin) Presentations at the..
BU
11/02SEAGEN : to Host Virtual R&D Day on November 16, 2020
BU
10/30SEAGEN : Management's Discussion and Analysis of Financial Condition and Results..
AQ
10/29SEATTLE GENETICS : 3Q Earnings Snapshot
AQ
10/29SEAGEN INC. : Results of Operations and Financial Condition (form 8-K)
AQ
10/29SEAGEN : Reports Third Quarter 2020 Financial Results
BU
10/29SEAGEN : Announces Closing of $1.0 Billion Stock Sale to Merck
AQ
10/28SEAGEN : Announces Closing of $1.0 Billion Stock Sale to Merck
BU
More news
Financials (USD)
Sales 2020 2 155 M - -
Net income 2020 588 M - -
Net cash 2020 1 959 M - -
P/E ratio 2020 54,4x
Yield 2020 -
Capitalization 31 988 M 31 988 M -
EV / Sales 2020 13,9x
EV / Sales 2021 16,4x
Nbr of Employees 1 605
Free-Float 99,4%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 198,39 $
Last Close Price 177,41 $
Spread / Highest target 43,2%
Spread / Average Target 11,8%
Spread / Lowest Target -22,2%
EPS Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Robert J. Lechleider Senior Vice President-Clinical Development
Roger D. Dansey Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SEAGEN INC.55.27%31 988
MODERNA, INC.620.91%55 799
LONZA GROUP AG56.57%45 596
CELLTRION, INC.87.85%41 539
IQVIA HOLDINGS INC.10.82%32 829
IMMUNOMEDICS, INC.315.22%20 324